Home/ Stocks/ CVM

Cel-Sci Corporation

CVM XASE

$1.72 +0.11 (+6.83%) ▲ 15-min delayed

Open

$1.63

High

$1.73

Low

$1.57

Volume

249.5K

Market Cap

$28.14M

About Cel-Sci Corporation

CEL-SCI Corp is a late clinical-stage biotechnology company dedicated to research and development directed at improving the treatment of cancer and other diseases by using the immune system, the body's natural defense system. The company is focused on the development of the following product candidates and technologies: 1) Multikine, an investigational Phase 3 immunotherapy under development for the potential treatment of certain head and neck cancers; 2) LEAPS (Ligand Epitope Antigen Presentation System) technology, for the potential treatment of rheumatoid arthritis.

Sector: BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) Employees: 44 Website →

Key Financials

Period	Revenue	Net Income	EPS
Q2 2026	$-117,485	$5.47M	N/A
Q1 2026	$-87,789	$5.47M	N/A
FY 2025	$-648,944	$25.41M	N/A
Q3 2025	$-172,050	$-5,664,704	N/A

Related Market News

No specific coverage for CVM yet. Check out our latest market news or earnings calendar.

Get CVM Alerts

Stay ahead with breaking news, price alerts, and expert analysis on Cel-Sci Corporation.

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.